Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ventyx Biosciences Inc (VTYX)

Ventyx Biosciences Inc (VTYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 570,872
  • Shares Outstanding, K 71,359
  • Annual Sales, $ 0 K
  • Annual Income, $ -135,120 K
  • EBIT $ -117 M
  • EBITDA $ -115 M
  • 60-Month Beta 1.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.92

Options Overview Details

View History
  • Implied Volatility 115.83% (-0.07%)
  • Historical Volatility 105.13%
  • IV Percentile 15%
  • IV Rank 7.51%
  • IV High 796.79% on 04/07/25
  • IV Low 60.57% on 09/02/25
  • Expected Move (DTE 13) 1.36 (15.60%)
  • Put/Call Vol Ratio 1.11
  • Today's Volume 11,891
  • Volume Avg (30-Day) 2,888
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 58,269
  • Open Int (30-Day) 49,048
  • Expected Range 7.36 to 10.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.41
  • Number of Estimates 4
  • High Estimate -0.32
  • Low Estimate -0.49
  • Prior Year -0.41
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.60 +14.74%
on 12/04/25
10.55 -17.33%
on 11/26/25
-0.28 (-3.11%)
since 11/05/25
3-Month
2.26 +286.70%
on 09/16/25
10.55 -17.33%
on 11/26/25
+6.20 (+246.03%)
since 09/05/25
52-Week
0.78 +1,013.67%
on 04/07/25
10.55 -17.33%
on 11/26/25
+6.21 (+247.41%)
since 12/05/24

Most Recent Stories

More News
Ventyx Provides Clinical and Corporate Updates

Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical Advisor Expanding the Phase 2 recurrent pericarditis study into Canada, EU and...

VTYX : 8.72 (+9.00%)
Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies...

VTYX : 8.72 (+9.00%)
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies...

VTYX : 8.72 (+9.00%)
Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Data from the recent Phase 2 study position Ventyx’s NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a biomarker...

VTYX : 8.72 (+9.00%)
Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the...

VTYX : 8.72 (+9.00%)
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies...

VTYX : 8.72 (+9.00%)
Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson’s disease Data from the Phase 2 study of VTX2735 in patients with...

VTYX : 8.72 (+9.00%)
Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease

VTYX : 8.72 (+9.00%)
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

VTYX : 8.72 (+9.00%)
Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

VTYX : 8.72 (+9.00%)

Business Summary

Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on advancing new therapies for patients living with inflammatory diseases and autoimmune disorders. The company's clinical stage pipeline includes VTX958, VTX002 and VTX2735. Ventyx Biosciences Inc. is headquartered in...

See More

Key Turning Points

3rd Resistance Point 10.36
2nd Resistance Point 9.68
1st Resistance Point 9.20
Last Price 8.72
1st Support Level 8.04
2nd Support Level 7.36
3rd Support Level 6.88

See More

52-Week High 10.55
Last Price 8.72
Fibonacci 61.8% 6.82
Fibonacci 50% 5.67
Fibonacci 38.2% 4.51
52-Week Low 0.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar